Cancer
Conditions
Brief summary
This study is looking at the feasibility of performing frailty assessments on elderly patients with advanced cancers
Detailed description
This study is primarily looking to see if it is feasible to assess frailty in patients age 70 years and above with advanced cancers. it is also evaluating whether there may be any correlation between these assessments and toxicity and treatment and outcome. The assessments include: Frailty score, nutritional assessment, comorbidity score and quality of life. In addition sarcopenia will be assessed using timed walk, grip strength and muscle mass measurement from imaging performed as part of routine clinical care. The assessments will be performed at baseline, week 12 and week 24. There is the option for patients to also donate blood samples for research purposes.
Interventions
None listed
Sponsors
Newcastle-upon-Tyne Hospitals NHS Trust
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histological diagnosis of advanced carcinoma - not suitable for curative treatment * Age 70 years or over * seen by an oncologist for consideration of palliative systemic medical therapy and decision regarding management already made * WHO Performance Status 0-2 * Written informed consent
Exclusion criteria
* Hepatocellular cancer * Prostate cancer * Breast cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage patients consenting for assessments out of number approached | Baseline | Number of patients consenting for the study as a percentage of number of patients approached about the study. |
| Time taken to complete assessments | Baseline, week 12 and week 24 | Length of time participants take to complete study assessments |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frailty as a predictor of grade 3/4 toxicity | baseline | Evaluate whether there is a possible correlation between frailty score at baseline and development of grade 3/4 toxicity during anticancer treatment |
| Sarcopenia as a predictor of outcome | baseline, week 12 and week 24 | sarcopenia at baseline and over time as a predictor of outcome |
| Quality of life EORTC QCQ 30 | baseline, week 12 and week 24 | Participants complete EORTC QCQ 30 questionnaire |
| Biomarker assessment of frailty and associated factors which may include genetic analysis | baseline, week 12 and week 24 | Assessment of frailty biomarkers in blood samples |
Countries
United Kingdom
Outcome results
None listed